Search

Background: Previous studies have revealed that relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) could be predicted by monitoring Wilms' tumor 1 (WT1) mRNA expression. However, only a few studies have investigated patients who received human leukocyte antigen-haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCY-haplo). In this study, we investigated the relationship between WT1 mRNA levels and clinical outcomes in the PTCY-haplo group, and compared them with those in the conventional graft-versus-host disease prophylaxis group (conventional group). Methods: We retrospectively analyzed 130 patients who received their first allo-HSCT between April 2017 and December 2020, including 26 who received PTCY-haplo. Results: The WT1 mRNA expression level at day + 30 after allo-HSCT associated with increased risk of 1-year cumulative incidence of relapse (CIR) was ≥ 78 copies/μg RNA in the conventional group (p < 0.01) and ≥ 50 copies/μg RNA in the PTCY-haplo group (p = 0.03). Conclusions: The appropriate cutoff level of WT1 mRNA at day + 30 after allo-HSCT for predicting prognosis in patients treated with PTCY-haplo may be < 50 copies/μg RNA. [ABSTRACT FROM AUTHOR]

Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune intensity after PTCy for each patient's condition have not been well studied. Here, we investigated the effects of reducing the dose of PTCy followed by α-galactosylceramide (α-GC), a ligand of iNKT cells, on the reciprocal balance between graft-versus-host disease (GVHD) and the graft-versus-leukemia (GVL) effect. In a murine haploidentical HSCT model, insufficient GVHD prevention after reduced-dose PTCy was efficiently compensated for by multiple administrations of α-GC. The ligand treatment maintained the enhanced GVL effect after reduced-dose PTCy. Phenotypic analyses revealed that donor-derived B cells presented the ligand and induced preferential skewing to the NKT2 phenotype rather than the NKT1 phenotype, which was followed by the early recovery of all T cell subsets, especially CD4+Foxp3+ regulatory T cells. These studies indicate that α-GC administration soon after reduced-dose PTCy restores GVHD-preventing activity and maintains the GVL effect, which is enhanced by reducing the dose of PTCy. Our results provide important information for the development of a novel strategy to optimize PTCy-based transplantation, particularly in patients with a potential relapse risk. [ABSTRACT FROM AUTHOR]

Creatinine clearance rate (Ccr) is a more accurate indicator of renal function than serum creatinine. Data are sparse regarding the prognostic value of renal impairment calculated using Ccr in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective analysis of 185 patients who underwent allo-HSCT. These patients were divided into two groups by Ccr (ml/min) before transplantation; one showed normal renal function (Ccr ≥ 60, n = 156) and the other showed mild renal dysfunction (30 ≤ Ccr < 60, n = 29), and transplant outcomes were compared between the groups. We observed no significant difference between the groups in terms of clinical characteristics other than age, estimated glomerular filtration rate, serum creatinine, Ccr predicted by Cockcroft-Gault formula, primary disease, and conditioning intensity. With respect to transplant outcomes, no significant difference was observed in overall survival, relapse, or non-relapse mortality between the two groups. Multivariate analysis demonstrated that 30 ≤ Ccr < 60 before allo-HSCT was not an independent prognostic factor for transplant outcome. In conclusion, these results suggest that patients with mild renal dysfunction, defined as 30 ≤ Ccr < 60 ml/min, can safely undergo allo-HSCT. However, a larger series of patients is needed to evaluate the impact of mild renal dysfunction before allo-HSCT in more detail. [ABSTRACT FROM AUTHOR]

The distribution of starch granules in ungerminated seeds of Zostera marina was examined by electron microscopy and histochemistry. Quantitative changes during germination in starch and sugars [glucose/maltosaccharides (MS), sucrose, and fructose] were examined in the seeds using biochemical methods. At natural seawater salinity (30.2 psu), the number of starch granules and the amount of starch markedly decreased, resulting in no increase in the sugar content in the embryos during the early germination stage. A substantial increase in sugars in the shoots occurred after the development of true leaves, probably due to photosynthetic activity in the green true leaves. At natural seawater salinity, the amount of starch did not significantly change during the initial 14 days of germination. In contrast, at lower salinities, starch levels decreased significantly from day 0 to day 6, resulting in higher levels of glucose/MS and fructose in the basal hypocotyls. These results suggest that compared with the salinity of natural seawater, lower salinity may interfere with starch catabolism in seeds, thereby causing the seed coat to break open earlier. [ABSTRACT FROM AUTHOR]

How Zostera marina L. adapts to environmental stresses is of major interest to researchers wanting to obtain a better understanding of how to preserve this ecologically important seagrass. We have examined the structure and chemical properties of the cuticle and epidermal walls of Z. marina cotyledons at the pre-germination stage by microscopy, histochemistry, and chemical analyses. The epidermal cells, which have a smooth plasma membrane and slight wall-ingrowth, are surrounded by thickened outer tangential walls consisting of cellulose and pectic substances. The thick cuticle layer covers the outer surface of the outer tangential walls; the former were observed here to be much thicker than has been reported earlier for the leaves and sheaths of Z. marina. Chemical analysis of the isolated cuticle by attenuated total reflectance–infrared Fourier transform spectrometry and gas chromatography–mass spectrometry detected C16 and C18 fatty acids, ω-hydroxy fatty acids and β-sitosterol as components of the wax and cutin. The outermost cuticle layer was also observed to be covered with a slimy layer consisting of some polysaccharides. These results suggest that the extremely thick cuticle and slimy layer could play a significant role in protecting the cotyledons from environmental stresses at the pre-emergence stage and just after emergence. [ABSTRACT FROM AUTHOR]

An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]

Photodynamic therapy (PDT) is an emerging treatment for various solid cancers. We recently reported that tumor cell lines and patient specimens from adult T cell leukemia/lymphoma (ATL) are susceptible to specific cell death by visible light exposure after a short-term culture with 5-aminolevulinic acid, indicating that extracorporeal photopheresis could eradicate hematological tumor cells circulating in peripheral blood. As a bridge from basic research to clinical trial of PDT for hematological malignancies, we here examined the efficacy of ALA-PDT on various lymphoid malignancies with circulating tumor cells in peripheral blood. We also examined the effects of ALA-PDT on tumor cells before and after conventional chemotherapy. With 16 primary blood samples from 13 patients, we demonstrated that PDT efficiently killed tumor cells without influencing normal lymphocytes in aggressive diseases such as acute ATL. Importantly, PDT could eradicate acute ATL cells remaining after standard chemotherapy or anti-CCR4 antibody, suggesting that PDT could work together with other conventional therapies in a complementary manner. The responses of PDT on indolent tumor cells were various but were clearly depending on accumulation of protoporphyrin IX, which indicates the possibility of biomarker-guided application of PDT. These findings provide important information for developing novel therapeutic strategy for hematological malignancies. [ABSTRACT FROM AUTHOR]